Country: United Kingdom
Language: English
Source: myHealthbox
leuprorelin acetate
GP-PHARM, S.A
L02AE02
leuprorelin acetate
22.5mg
Powder and solvent for prolonged-release suspension for injection
intramuscular route
One (1) type I glass vial containing 22.5 mg
POM - Prescription Only Medicine
GP-PHARM, S.A
Hormones and related agents. Gonadotropin-releasing hormones analogues
It is indicated for palliative treatment of hormone dependent advanced prostate cancer.
Authorised
2015-05-22
PACKAGE LEAFLET: INFORMATION FOR THE USER LUTRATE DEPOT 22.5 MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION leuprorelin acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lutrate Depot is and what it is used for 2. What you need to know before you use Lutrate Depot 3. How to use Lutrate Depot 4. Possible side effects 5. How to store Lutrate Depot 6. Contents of the pack and other information 1. WHAT LUTRATE DEPOT IS AND WHAT IT IS USED FOR _ _ Lutrate Depot is a vial containing a white powder, which is made into a suspension for injection into a muscle. Lutrate Depot contains the active ingredient leuprorelin (also called LEUPROLIDE), which belongs to a group of medicines called luteinizing hormone releasing hormone (LHRH) agonists (medicines that reduce testosterone – a sex hormone). Your doctor has prescribed Lutrate Depot for_ _palliative treatment of advanced prostate cancer. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE LUTRATE DEPOT DO NOT USE LUTRATE DEPOT: - if you are allergic (hypersensitive) to LHRH, LHRH agonists or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lutrate Depot 22.5 mg powder and solvent for prolonged-release suspension for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 22.5 mg of leuprorelin acetate (equivalent to 21.42 mg leuprorelin free base). 1 ml of reconstituted suspension contains 11.25 mg of leuprorelin acetate. _Excipients with known effect: _ Each vial contains from 1.6 to 2.7 mg (<1 mmol) of sodium (as carmellose sodium). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for prolonged-release suspension for injection. Powder: white to off-white powder. Solvent: clear, colorless and particle free solution (pH 5.0 – 7.0). 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lutrate Depot is indicated for palliative treatment of hormone dependent advanced prostate cancer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The usual recommended dose of Lutrate Depot 22.5 mg presented as a three months depot injection and administered as a single intramuscular injection every three months. Lutrate Depot must be administered under direction of healthcare professional having the appropriate expertise for monitoring the response to treatment. The dose of Lutrate Depot 22.5 mg allowing the continuous release of leuprorelin acetate over a three month period is incorporated in a depot formulation. The lyophilized powder should be reconstituted and administered as a single intramuscular injection every three months. Intraarterial or intravenous administration must be avoided. The vial of Lutrate Depot microsphere powder should be reconstituted immediately prior to administration by intramuscular injection. As with other drugs administered regularly by injection, the injection site should be varied periodically. Read the complete document